Personalized Pathways: Muscle Invasive Bladder Cancer Care 2026 - Patient Perspective
Duration: 15m 35s
Free, Online
2 days ago
Personalized Pathways: Muscle Invasive Bladder Cancer Care 2026 | Part 2: Coordinating ctDNA Testing Across the Care Continuum
Duration: 17m 58s
Personalized Pathways: Muscle Invasive Bladder Cancer Care 2026 | Part 3: Applying ctDNA Results to Guide Individualized Care
Duration: 15m 2s
Personalized Pathways: Muscle Invasive Bladder Cancer Care 2026 | Part 1: Understanding the Dual Role of ctDNA
Duration: 15m 7s
mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways - Patient Perspective
Duration: 17m 45s
7 days ago
Personalized Pathways: Muscle Invasive Bladder Cancer Care 2026
3rd Mar 2026, 12:30am (GMT)
Global mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways
25th Feb 2026, 2:00pm (GMT)
mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways | Part 4: Emerging Non-Chemo Options
Duration: 20m 30s
22 days ago
mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways | Part 3: Epigenetic Rationale
Duration: 15m 1s
mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways | Part 2: Sequencing After ARPI
Duration: 19m 45s
mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways | Part 1: Decoding Resistance Biology
Duration: 15m 12s
mCRPC Synergy Series: Overcoming Resistance and Optimizing Pathways
24th Feb 2026, 12:30am (GMT)
HER2+ MBC Updates from San Antonio Breast Cancer Symposium 2025
Updated 19 Jan 2026
Optimizing Maintenance in HER2+ Metastatic Breast Cancer: A thread
Updated 12 Feb 2026
1L HER2+ / HR+ MBC: Integration Map
Key Clinical Summary: BRAF-driven treatment decisions - The patient perspective
Key Clinical Summary: BRAF-driven treatment decisions - Biomarker testing in practice
Key Clinical Summary: BRAF-driven treatment decisions - First line personalization and adverse events management
Key Clinical Summary: Optimizing Maintenance in HER2+ Metastatic Breast Cancer
Key Clinical Summary: The Role of Endocrine Therapy ± CDK4/6 Inhibitors in HER2+/HR+ MBC 1L Setting
